Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Revive Therapeutics (RVVTF) AI Stock Analysis

RVVTF

Revive Therapeutics

(Other OTC:RVVTF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low Debt BurdenVery low debt reduces near-term refinancing pressure and interest obligations while the company remains in development. This provides some financial flexibility to direct available resources toward clinical programs, intellectual property, and regulatory work, although it does not eliminate broader funding needs.
Negative Factors
No Commercial RevenueThe absence of revenue means Revive has not yet demonstrated commercial demand or an operating model that funds itself. Until a candidate reaches approval and sales, future progress depends on development execution and access to capital rather than recurring customer income.

Revive Therapeutics (RVVTF) vs. SPDR S&P 500 ETF (SPY)

-100%0%100%200%300%400%500%RVVTF+40.00%SPY+11.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
$8.71M
Dividend Yield
―
Average Volume (3M)
169.47K
Price to Earnings (P/E)
-0.8
Beta (1Y)
-1.72
Revenue Growth
―
EPS Growth
91.01%
Country
US
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Revive Therapeutics Business Overview & Revenue Model

Company Description

Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory...

Revive Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RVVTF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:RAMMTSE:RAMM42NeutralCAD 1.19M-0.13-194.41%―-66.40%31.38%
TSE:PCLOTSE:PCLO24UnderperformCAD 9.34M-2.6728.59%―0.90%57.73%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%400%RVVTFTSE:PCLOTSE:RAMMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
RVVTF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RVVTFRevive Therapeutics0.010.0040.00%
TSE:PCLOPharmacielo0.050.0111.11%
TSE:RAMMRamm Pharma Corp0.01-0.01-50.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.